{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:18:39Z","timestamp":1783354719861,"version":"3.54.6"},"reference-count":24,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The World Health Organization recommends screening and providing preventive treatment of tuberculosis in high-risk groups. We compared the performance of the latest versions of two widely used interferon (IFN)-\u03b3 release assays (IGRAs), the QuantiFERON-TB Gold Plus chemiluminescent assay (QFT-Plus CLIA) and the semi-automated T-SPOT.TB assay, and assessed the potential benefit of a dual-testing strategy in immunosuppressed patients and\/or candidates for biological therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From September 2022 to December 2023, we included 3748 immunosuppressed patients. IGRAs were performed according to manufacturers\u2019 instructions. Agreement was evaluated using Cohen's kappa (\u03ba), and subgroup analyses were stratified by age and underlying disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At least one IGRA was positive in 13.4% of patients (12.0% QFT-Plus CLIA; 9.9% T-SPOT.TB). Indeterminate results were infrequent (1.8% QFT-Plus CLIA; 2.6% T-SPOT.TB). Overall agreement was high (93.0%; \u03ba=0.67), but lower among IGRA-positive cases (63.9%; \u03ba=0.62). Discrepancies occurred in 7.0% of patients, most frequently in children (0\u201314\u2005years: 15.4%), older adults (\u226575\u2005years: 13.8%), individuals living with HIV (38%), rheumatoid arthritis\/Sj\u00f6gren's syndrome (12.4%) and other chronic inflammatory diseases, transplant recipients or immunodeficiencies (11.9%). Among IGRA-positive cases (n=502), most discordant results corresponded to QFT-Plus CLIA-positive\/T-SPOT.TB-negative patterns (131 of 181; 72.4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In immunosuppressed patients, dual IGRA testing enhances diagnostic sensitivity and can strengthen clinical decision-making. Concordant results increase diagnostic certainty, whereas discordant findings gain interpretative value when contextualised by disease group and assay-specific behaviour IGRA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01257-2025","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:45:21Z","timestamp":1766079921000},"page":"01257-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Fourth-generation chemiluminescence QuantiFERON-TB Plus assay\n                    <i>versus<\/i>\n                    T-SPOT.TB semi-automated assay: a case for the use of both assays in immunosuppressed patients"],"prefix":"10.1183","volume":"12","author":[{"given":"Sergio","family":"Palacios-Penedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Arias-Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-1035","authenticated-orcid":false,"given":"Patricio","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Castell\u00f3-Abietar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0522-6872","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Men\u00e9ndez-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Ram\u00edrez-Parras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primitivo","family":"Buend\u00eda-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-6230","authenticated-orcid":false,"given":"Jos\u00e9-Mar\u00eda","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Riestra-Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-456X","authenticated-orcid":false,"given":"Victor","family":"Asensi-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Jos\u00e9","family":"Palacios-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026070608550804000_12.3.01257-2025.1","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva, World Health Organization, 2022. www.who.int\/publications\/i\/item\/9789240046764"},{"key":"2026070608550804000_12.3.01257-2025.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150057"},{"key":"2026070608550804000_12.3.01257-2025.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567"},{"key":"2026070608550804000_12.3.01257-2025.4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5021\/ad.2021.33.1.77","article-title":"Disseminated tuberculosis in a psoriasis patient under adalimumab treatment despite the chemoprophylaxis of latent tuberculosis: a case report","volume":"33","author":"Oh","year":"2021","journal-title":"Ann Dermatol"},{"key":"2026070608550804000_12.3.01257-2025.5","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection. Geneva, World Health Organization, 2022. www.who.int\/publications\/i\/item\/9789240056084"},{"key":"2026070608550804000_12.3.01257-2025.6","unstructured":"World Health Organization . Use of alternative interferon-gamma release assays for the diagnosis of TB infection: WHO policy statement. Geneva, World Health Organization, 2022. www.who.int\/publications\/i\/item\/9789240042346"},{"key":"2026070608550804000_12.3.01257-2025.7","doi-asserted-by":"crossref","first-page":"904308","DOI":"10.3389\/fimmu.2022.904308","article-title":"Significant difference in Th1\/Th2 paradigm induced by tuberculosis-specific antigens between IGRA-positive and IGRA-negative patients","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"2026070608550804000_12.3.01257-2025.8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw694"},{"key":"2026070608550804000_12.3.01257-2025.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0430OC"},{"key":"2026070608550804000_12.3.01257-2025.10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.arbres.2020.04.011","article-title":"Diagnosis of tuberculous infection in immunosuppressed patients and\/or candidates for biologics using a combination of 2 IGRA Tests: T-SPOT.TB\/QuantiFERON-TB gold in-tube vs. T-SPOT.TB\/QuantiFERON-TB gold plus","volume":"58","author":"Fern\u00e1ndez-Bl\u00e1zquez","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"2026070608550804000_12.3.01257-2025.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00510-2016"},{"key":"2026070608550804000_12.3.01257-2025.12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02498-16"},{"key":"2026070608550804000_12.3.01257-2025.13","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00614-18"},{"key":"2026070608550804000_12.3.01257-2025.14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tube.2017.11.014","article-title":"A multicentre verification study of the QuantiFERON-TB Gold Plus assay","volume":"108","author":"Pieterman","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"2026070608550804000_12.3.01257-2025.15","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00985-19"},{"key":"2026070608550804000_12.3.01257-2025.16","doi-asserted-by":"crossref","first-page":"e0060321","DOI":"10.1128\/JCM.00603-21","article-title":"Evaluation of the fully automated chemiluminescence analyzer liaison XL for the performance of the QuantiFERON-TB Gold Plus assay in an area with a low incidence of tuberculosis","volume":"59","author":"Fern\u00e1ndez-Huerta","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2026070608550804000_12.3.01257-2025.17","doi-asserted-by":"crossref","first-page":"115613","DOI":"10.1016\/j.diagmicrobio.2021.115613","article-title":"Comparison of the QuantiFERON-TB Gold Plus on LIAISON XL and T-SPOT.TB for the diagnosis of latent Mycobacterium tuberculosis infection in a low tuberculosis incidence population","volume":"102","author":"Heireman","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026070608550804000_12.3.01257-2025.18","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01436-20"},{"key":"2026070608550804000_12.3.01257-2025.19","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/medicina59101734","article-title":"Evaluation of a new chemiluminescent immunoassay-based interferon-gamma release assay for detection of latent tuberculosis infection","volume":"59","author":"Kim","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2026070608550804000_12.3.01257-2025.20","doi-asserted-by":"crossref","first-page":"e0029523","DOI":"10.1128\/jcm.00295-23","article-title":"Inflated gamma interferon response with QuantiFERON-TB Gold Plus using the automated Liaison XL Analyzer: a testing algorithm to mitigate false-positive results in low-incidence settings","volume":"61","author":"Buron","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2026070608550804000_12.3.01257-2025.21","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00780-20"},{"key":"2026070608550804000_12.3.01257-2025.22","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.3748\/wjg.v24.i25.2764","article-title":"Systematic review and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with tumor necrosis factor-\u03b1 inhibitors (anti-TNF\u03b1)","volume":"24","author":"Cao","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026070608550804000_12.3.01257-2025.23","doi-asserted-by":"crossref","first-page":"e0055122","DOI":"10.1128\/jcm.00551-22","article-title":"Novel automation of an enzyme-linked immunosorbent spot assay testing method: comparable diagnostic performance of the T-SPOT.TB test using manual density gradient cell isolation versus automated positive selection with the T-cell select kit","volume":"60","author":"Wang","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2026070608550804000_12.3.01257-2025.24","first-page":"525","article-title":"Performance of the T-SPOT.TB test in patients with indeterminate QuantiFERON-TB Gold Plus results: proposal for an algorithm for the diagnosis of latent tuberculosis infection","volume":"32","author":"Pagnoncelli","year":"2024","journal-title":"Infez Med"}],"updated-by":[{"DOI":"10.1183\/23120541.51257-2025","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000}}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01257-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:55:29Z","timestamp":1783353329000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01257-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1183\/23120541.01257-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01257-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}